Action TBIO TELESIS BIO, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Telesis Bio, Inc.

Actions

TBIO

US1920032000

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 07/06/2024 		Varia. 5j. Varia. 1 janv.
3,8 USD 0,00 % Graphique intraday de Telesis Bio, Inc. -6,86 % -47,09 %
09/05 Telesis Bio, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
18/04 Telesis Bio, Inc. annonce la nomination d'Eric Esser au conseil d'administration CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Telesis Bio: Q1 Earnings Snapshot
AQ
Telesis Bio Reports First Quarter 2024 Financial Results
GL
Telesis Bio Announces Reverse Stock Split
GL
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
GL
Telesis Bio : Shareholder Meeting - Form 8-K
PU
Telesis Bio: Q4 Earnings Snapshot
AQ
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA
AQ
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
GL
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
AQ
Thinking about buying stock in Telesis Bio, Sellas Life Sciences, Mitek Systems, Monopar Therapeutics, or Inpixon?
PR
Telesis Bio Reports Third Quarter 2023 Financial Results
GL
Telesis Bio Reports Third Quarter 2023 Financial Results
AQ
Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
GL
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
GL
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
AQ
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
GL
Telesis Bio Appoints William J. Kullback Chief Financial Officer
GL
Telesis Bio Appoints William J. Kullback Chief Financial Officer
AQ
Telesis Bio Reports Second Quarter 2023 Financial Results
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TBIO
  4. Actualités Telesis Bio, Inc.
  5. Communiqués